Beam Therapeutics Dives On $120 Million Takeover Of Guide Therapeutics

Beam Therapeutics announced it had acquired Guide Therapeutics, a maker of components for genetic medicines — and Beam stock tumbled. Broadly, biotech stocks were under pressure.